Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 300

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation

Open access
Schmid, Christoph, Labopin, Myriam, Nagler, Arnon, Niederwieser, Dietger, Castagna, Luca, Tabrizi, Reza, Stadler, Michael, Kuball, Jürgen, Cornelissen, Jan, Vorlicek, Jiri, Socié, Gerard, Falda, Michele, Vindeløv, Lars, Ljungman, Per, Jackson, Graham, Kröger, Nicolaus, Rank, Andreas, Polge, Emmanuelle, Rocha, Vanderson, Mohty, Mohamad, on behalf of the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)·2012·Blood
DOI 10.1182/blood-2011-08-375840
Open this paper in CoChat — free account

Abstract

Because information on management and outcome of AML relapse after allogeneic hematopoietic stem cell transplantation (HSCT) with reduced intensity conditioning (RIC) is scarce, a retrospective registry study was performed by the Acute Leukemia Working Party of EBMT. Among 2815 RIC transplants performed for AML in complete remission (CR) between 1999 and 2008, cumulative incidence of relapse was 32% ± 1%. Relapsed patients (263) were included into a detailed analysis of risk factors for overall survival (OS) and building of a prognostic score. CR was reinduced in 32%; remission duration after transplantation was the only prognostic factor for response (P = .003). Estimated 2-year OS from relapse was 14%, thereby resembling results of AML relapse after standard conditioning. Among variables available at the time of relapse, remission after HSCT > 5 months (hazard ratio [HR] = 0.50, 95% confidence interval [CI], 0.37-0.67, P < .001), bone marrow blasts less than 27% (HR = 0.53, 95% CI, 0.40-0.72, P < .001), and absence of acute GVHD after HSCT (HR = 0.67, 95% CI, 0.49-0.93, P = .017) were associated with better OS. Based on these factors, 3 prognostic groups could be discriminated, showing OS of 32% ± 7%, 19% ± 4%, and 4% ± 2% at 2 years (P < .0001). Long-term survival was achieved almost exclusively after successful induction of CR by cytoreductive therapy, followed either by donor lymphocyte infusion or second HSCT for consolidation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-08-375840

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 300

Metadata

Authors
Schmid, C., Labopin, M., Nagler, A., Niederwieser, D., Castagna, L., Tabrizi, R., Stadler, M., Kuball, J., Cornelissen, J., Vorlicek, J., Socié, G., Falda, M., Vindeløv, L., Ljungman, P., Jackson, G., Kröger, N., Rank, A., Polge, E., Rocha, V., Mohty, M., & on behalf of the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Venue
Blood
Publisher
American Society of Hematology
Published
2012-02-09
Volume
119
Issue
6
Pages
1599-1606
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood-2011-08-375840
OpenAlex
W2074326274
Cited by
300
References
35
FWCI
8.68
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. https://app.cochat.ai/papers/10.1182/blood-2011-08-375840
The paper
Schmid, C., Labopin, M., Nagler, A., Niederwieser, D., Castagna, L., Tabrizi, R., Stadler, M., Kuball, J., Cornelissen, J., Vorlicek, J., Socié, G., Falda, M., Vindeløv, L., Ljungman, P., Jackson, G., Kröger, N., Rank, A., Polge, E., Rocha, V., . . . on behalf of the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). (2012). Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. https://doi.org/10.1182/blood-2011-08-375840

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.